Tricida Inc (NASDAQ:TCDA) insider Gerrit Klaerner sold 4,000 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $31.17, for a total transaction of $124,680.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Gerrit Klaerner also recently made the following trade(s):
- On Monday, July 8th, Gerrit Klaerner sold 5,826 shares of Tricida stock. The shares were sold at an average price of $35.55, for a total transaction of $207,114.30.
TCDA traded up $1.15 during trading on Tuesday, reaching $32.36. The company’s stock had a trading volume of 113,780 shares, compared to its average volume of 294,410. The company has a current ratio of 8.30, a quick ratio of 8.30 and a debt-to-equity ratio of 0.24. The stock has a fifty day simple moving average of $34.94. Tricida Inc has a 1 year low of $19.43 and a 1 year high of $42.80. The company has a market capitalization of $1.53 billion and a P/E ratio of -6.97.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio lifted its stake in Tricida by 8.3% in the 2nd quarter. Strs Ohio now owns 5,200 shares of the company’s stock worth $205,000 after purchasing an additional 400 shares in the last quarter. FMR LLC lifted its stake in Tricida by 9.7% in the 1st quarter. FMR LLC now owns 1,213,065 shares of the company’s stock worth $46,849,000 after purchasing an additional 107,500 shares in the last quarter. MetLife Investment Advisors LLC lifted its stake in Tricida by 68.8% in the 1st quarter. MetLife Investment Advisors LLC now owns 8,804 shares of the company’s stock worth $340,000 after purchasing an additional 3,587 shares in the last quarter. Marshall Wace North America L.P. lifted its stake in Tricida by 99.0% in the 1st quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock worth $100,000 after purchasing an additional 1,289 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Tricida in the 1st quarter worth approximately $2,546,000. 62.89% of the stock is currently owned by institutional investors and hedge funds.
TCDA has been the topic of a number of research reports. Needham & Company LLC raised their price target on shares of ViaSat from $78.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 24th. Empire raised their price target on shares of Tricida from $37.00 to $58.00 in a research note on Monday, April 1st. Zacks Investment Research lowered shares of Farmland Partners from a “hold” rating to a “sell” rating in a research note on Friday, July 12th. Cowen reaffirmed a “buy” rating and issued a $50.00 price target on shares of Tricida in a research note on Tuesday, June 25th. Finally, Goldman Sachs Group initiated coverage on shares of Tricida in a research note on Wednesday, June 26th. They issued a “buy” rating and a $48.00 price target on the stock.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Recommended Story: How Does the Quiet Period Work?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.